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ACUTE PERICARDITIS 
GOAL
On example of case history to reveal 
clinical course and management of 
patient with acute  pericarditis
RELEVANCE
Three main considerations of David H. Spodick: 
1) pericarditis occurs in every category of 
disease, common and exotic (the spectrum is 
so broad that with every new case, the clinician 
should devise an appropriate differential 
diagnosis) 
2) to avoid therapeutic mishaps, pericarditis 
must not be mistaken for other syndromes, 
and 
3) the etiological and clinical spectra of acute 
pericarditis change frequently and some classic 
assumptions and descriptions are outdated
DEFINITION
Acute pericarditis is the inflammation of the 
pericardial sac (lining around the heart) 
caused by infectious or noninfectious noxa
with the possible increased production of 
pericardial fluid as exudate and less than 4 
weeks duration
http://www.medscape.com/viewarticle/751203
 Epidemiologic data are lacking, likely because this
condition is frequently inapparent clinically, 
despite its presence in numerous disorders
 Lorell noted a diagnosis acute pericarditis in
approximately 1 per 1000 hospital admissions
 Acute pericarditis comprises 1% of emergency
room visits in patients with ST-segment elevation
EPIDEMIOLOGY
http://emedicine.medscape.com/article/156951-overview#a7
Our Patient M. 
46 yr. old male
PRESENTING COMPLAINTS
 Dull, aching pain in retrosternal region of the chest 
with radiation to the cervical spine, shoulders, 
interscapular area 
 Pain is persistent and three weeks duration
 Pain becomes worse on inspiration and supine 
position
 Occasionally patient notes palpitations
 Other symptoms include: weakness, fatigue, high 
grade fever (39,5°C), body weight loss up to 2 kg 
HISTORY OF THE PRESENTING COMPLAINTS
 Three weeks prior to presentation, patient had been 
exposed to cold
 Since that moment in patient developed low grade 
fever (up to 37,5°C) and pain in the heart region 
 Patient thought he had been caught the cold, and had 
been used NSAIDs to relief symptoms
 However, symptoms were not reduced, and fever 
gradation increase up to 39,5°C
 General practitioner had prescribed for patient 
Amoxicillin 1000 mg tid
 Five days of treatment were not effective and patient 
had been referred to cardiologist 
PAST MEDICAL HISTORY
 In the 2013 year patient suffered from periodical 
dull pain in the heart region
 He had been investigated and had been treated by 
cardiologist; final diagnosis was: 
“Neurocirculatory asthenia on the background 
of chronic tonsillitis decompensation ”
 After treatment, symptoms decreased,  pain in the 
heart region bothered patient rare 
DRUG HISTORY
 Patient has not any current medications
ALLERGIES AND REACTIONS
 Patient has not any allergies
 Patient has not any reactions to drugs and medication
ALCOHOL AND SMOKING
 Patient consumes alcohol occasionally
 Patient smokes 20 cigarettes (1 pack) per day during 17 
year, what equals 17 pack-years
FAMILY HISTORY
 Patient has no risk factors for cardiovascular 
disease, his parents and relatives do not bother 
cardiovascular diseases 
SOCIAL HISTORY
 Married
 Live in rural area in house with his wife, son, and 
mother-in-low
 Unemployed 
EXAMINATION
Temperature
PS
BP
Respiratory rate 
High
Weight
BMI 
39,5o C
100 bpm
120/80 mm Hg
15 pm
186 cm
75 kg
21,7 kg/m2
VITAL SIGNS:
Fever  and tachycardia
GENERAL CONDITION
 Middle aged good mood man 
 He has correct orientation in space and 
surroundings
 The patient’s posture is active
 Patient is well developed, well nourished and his 
appearance is consistent with his stated age
EXAMINATION
EXAMINATION
SKIN & MUCOUS MEMBRANES
 Skin is pale pink and clear, rashes and hemorrhages 
are absent, skin turgor and elasticity are preserved 
 Subcutaneous fat tissue is mildly underdeveloped 
 Nails are without any abnormalities
 Mucous membranes are pink and wet
 Tongue is clear and wet
 Edema is absent
 Lymph nodes are not palpable
JOINTS, HEAD & NECK
 Joints have normal configuration, active and 
passive movements are painless
 The head examination is unremarkable
 The neck has normal shape and size, no visible 
enlargement of thyroid gland 
 Thyroid gland is palpated, size is increased 
insignificantly, painless, has smooth surface, 
homogeneous structure, nodules are not detected 
 JVP 5.0 cm above the sternal angle
EXAMINATION
RESPIRATORY & CARDIOVASCULAR SYSTEMS
 The chest has normal shape
 Vesicular breath sounds of the lungs to auscultation
 The point of apex beat is diffuse (3 cm in diameter), 
impulse is diminished force, unchanged location 
(palpated in the 5th intercostal space, 1,5 cm toward the 
sternum from left medclavicular line) 
 S1 and S2 are soft; diffuse holosystolic grade 3 murmur 
best heard at the apex
EXAMINATION
GIT & URINARY SYSTEMS
 Abdomen is soft and nontender
 Liver and spleen are not palpable
 The kidneys are not palpable
 Stool is normal
 Urination is normal
EXAMINATION
1ST LEVEL (all cases)
 Markers of inflammation (i.e. ESR, CRP, white blood 
cell count)
 Renal function and liver tests, thyroid function
 Markers of myocardial lesion (i.e. troponins, CK)
 ECG
 Echocardiography
 Chest X-Ray
2015 ESC RECOMMENDATIONS:
INVESTIGATIONS FOR ACUTE 
PERICARDITIS
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
2015 ESC RECOMMENDATIONS:
INVESTIGATIONS FOR ACUTE 
PERICARDITIS
2nd LEVEL (if 1st level is not sufficient for diagnostic 
purpose)
 CT and/or CMR
 Analysis of pericardial fluid from pericardiocentesis, or 
surgical dreinage, for
1. Cardiac tamponade or
2. Suspected bacterial, neoplastic pericarditis or
3. Symptomatic moderate to large effusions not responding 
to conventional anti-inflammatory therapy
Additional testing should be directed to specific etiologies 
according to clinical presentation (presence of high risk 
criteria)
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
HIHG RISK CRITERIA 
(at least 1 among the following)
Major
 High fever (>38⁰C)
 Subacute course without a clear-cut acute onset
 Large pericardial effusion (i.e. diastolic echo-free space >20 mm)
 Cardiac tamponade
 Failure to respond to NSAID therapy at least 1 week of therapy
Minor
 Myopericarditis
 Immunodepression
 Trauma
 Oral anticoagulant therapy
2015 ESC RECOMMENDATIONS:
INVESTIGATIONS FOR ACUTE 
PERICARDITIS
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
PATIENT’S PLAN OF SURVEY
Laboratory tests
 Complete blood count 
 Urinalysis 
 Biochemical blood profile: 
Bilirubin
ALT 
AST 
Thyroid function tests: TSH, T4
 Inflammation assessment: ESR, C-RP, RF
 Infection identification: ASL-O, PCR, blood culture
Creatinine
Urea
Potassium
Glucose
Cardiac biomarkers 
(Troponin I)
Instrumental investigations
 Thermometry 
 ECG
 Echocardiography
 Abdomen ultrasound
 Thyroid ultrasound
 Chest X-Ray
 Chest CT-scan
PATIENT’S PLAN OF SURVEY
Signs of inflammation: neutrophilic leucosytosis, shift to the left, 
increased ESR
LABORATORY TESTS
Complete blood count on the date of admission
ESR 34 mm/h
WBC (N 4.0-9.0 10*9/L) 13.9 *10⁹/L
NE (N 1.7-7.7 10*9/L; 47.0-72% ) 12.5 *10⁹/L 89.9%
Band neutrophils (1.06-6%) 14 %
Segmented neutrophils (47-72%) 75.9 %
LY (N 0.4-4.4 10*9/L; 19.0-37.0%) 0.7 *10⁹/L 5.3%
MO (N 0.0-0.8 10*9/L; 3.0-11.0%) 0.5 *10⁹/L 3.3%
E (N 0,0-0,6 10*9/L; 0,5-5,0%) 0.1 *10⁹/L 1.0%
BA (N 0.0-0.2 10*9/L; 0.0-1,0%) 0.1 *10⁹/L 0.5%
RBC (N 3.9-5.0 10*12/L) 4.20 *10¹²/L
Hb (N 120-160 g/L) 143 g/L
PLT (N180-320 10*9/L) 273 *10⁹/L
Urine analysis on the date of admission
Urine analysis falls in normal ranges
Colour Light yellow
Specific gravity (N 1,001-1,040) 1,015
pH (N 5,0-7,0) 6.0
Protein (N absent) Absent 
Glucose (N absent) Absent
Eritrocytes (N single) single
Leucocytes (N 6-8 in field) 1-3/HPF
Transitional epithelium (N single) sometimes
Casts: hyliane, granular, etc. (N single) Absent
Crystals (N absent) Absent
LABORATORY TESTS
Biochemical blood profile on the date of admission
Plasma glucose (3.9 - 6.4 venous blood) ̶ 4.1 mmol/L
All tests fall in reference range
Bilirubin Total 
(N 17 - 21 mkmol/L)
9.3
mkmol/L
Bilirubin Direct
(N 0 - 7,9 mkmol/L)
4.33
mkmol/L
Bilirubin Indirect
(N < 19 mkmol/L)
4.97
mkmol/L
ALT
(N < 41 U/L)
22 U/L
AST
(N < 35 U/L)
16 U/L
Creatinine 
(N 62-115
mkmol/L)
82
mkmol/L
LABORATORY TESTS
Troponin I 
(N < 0.01 ng/ml )
< 0.01 ng/ml
Troponin I falls in reference range, there is no evidence of 
cardiomyocyte damage
Biochemical blood profile on the date of admission
LABORATORY TESTS
Biochemical blood profile
on the date of admission
after 10 days of treatment
Signs of inflammation – raised level of C-RP, 
procalcitonin is slightly increased (range 0.47-0.50 
indicates low risk of severe sepsis and/or septic shock, 
>2 high risk)
C-RP
(N < 6 mg/L)
6-48 mg/L
Rheumatoid
factor
(N <8 IU/mL)
< 8 IU/mL
ASL-O
(N <200 IU/mL)
< 200
IU/mL
Procalcitonin
(<0.46 ng/mL)
0.48 
ng/mL
LABORATORY TESTS
TSH
(N 0.25-5 mkU/mL)
1.89 mkU/mL
TSH falls in reference range
To clarify thyroid dysfunction was recommended additional 
analysis: T4, TPO antibodies, Tg antibodies (to rule out 
autoimmune thyroiditis)
Biochemical blood profile on the date of admission
LABORATORY TESTS
Blood culture
Laboratory
Number
Culture Antibiotic sensitivity
#35-36 Pseudomonas
stutzeri
ceftriaxone, cefotaxime, ceftazidime, ceftazidime, 
cefixime, cefepime, ceflodoxime, amikacin, ofloxacin, 
ciprofloxacin, pefloxacin, levofloxacin, gatifloxacin
#37-38 Negative
#39-40 Enterococcus
faecium
amoxicillin, amoxiclav, rifampicin, chloramphenicol, 
doxycycline, vancomycin, azithromycin, levofloxacin, 
gatifloxacin, linezolid, netilmycin
Blood culture findings are diverse; it likely to be due to 
inappropriate blood sampling
LABORATORY TESTS
Serum PCR infection identification  
Infection Result
Herpes Simplex Virus type 1, 2 1.1
Varcisella Zoster Virus 1.2
Epstein Barr Virus 0.9
Cytomegalovirus 1.2
Human Herpes Virus type 6 0.8
Reference Range
0.5 – 1.09 negative
1.1 – 1.3   low viral load
1.4 – 1.6  medium viral load
1.7 – 1.9   high viral load
It occurs low viral load of herpes simplex virus type 1, 2 and 
cytomegalovirus, data are not sufficiently convincing for 
viral etiology of pericarditis
LABORATORY TESTS
ECG on the date of admission
INSTRUMENTAL INVESTIGATIONS
Sinus rhythm, 89 bpm, normal heart axis, PR-segment depression in II, 
III, AVF , PR-segment elevation in AVR, T waves flattened 
50 mm/s
I
II
III
AVR
AVL
AVF
V1
V2
V3
V4
V5
V6
ECG on the date of admission
Sinus rhythm, 89 bpm, normal heart axis, PR-segment depression in II, 
III, AVF, PR-segment elevation in AVR, T waves flattened
50 mm/s
I
II
III
AVR
AVL
AVF
V1
V2
V3
V4
V5
V6
INSTRUMENTAL INVESTIGATIONS
Echocardiography on the date of admission
 Heart chambers are not enlarged
 Pericardial effusion
posterior echo-free pericardial space 10 mm
anterior echo-free pericardial space 8 mm
apical echo-free pericardial space 8 mm
 Presence of floating fibrin threads
 Myocardial contractility is preserved, EF 76%
Signs of mixed serous-fibrinous pericardial effusion , 
mild severity
INSTRUMENTAL INVESTIGATIONS
Thyroid ultrasound on the date of admission
Thyroid hyperplasia II-III degree 
Diffuse changes of thyroid parenchyma and its hyperemia
Goiter II-III degree with hyperemia and diffuse changes 
of parenchyma
INSTRUMENTAL INVESTIGATIONS
Abdomen ultrasound on the date of admission
 Liver
 Pancreas
 Gallbladder
 Spleen is increased in size (135*63mm), diffuse changes of 
its parenchyma 
 Kidneys: microlithiasis (D 4.5-5.0mm)
Splenomegaly with diffuse changes of parenchyma 
unremarkable
INSTRUMENTAL INVESTIGATIONS
Chest X-Ray on the date of admission
 Focal and infiltrative changes is not observed
 Roots are structural, normal sized 
 Pleural sinuses are not changed
 Diaphragm clearly defined
 Heart is enlarged, left border is displaced to the left
 Aorta is not changed
Lungs are not changed; heart is enlarged
INSTRUMENTAL INVESTIGATIONS
Chest CT-scan
 Lungs are not changed
 Trachea and main bronchi are without any abnormalities
 Pulmonary trunk diameter 20 mm
 Left pulmonary artery diameter 19 mm
 Right pulmonary artery diameter 21 mm
 Mediastinal lymph nodes are up to 10 mm
 In pericardial sac occurs fluid with max thickness up to 20 
mm
 Destructive changes of bones are not observed
Pericardial effusion occurs
INSTRUMENTAL INVESTIGATIONS
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DYNAMIC OF BODY TEMPERATURE
day of disease
High grade fever occurs in initial stages, but resolved by the 
treatment
CONSULTATION 
Endocrinologist
Diffuse goiter I degree, euthyroidism
Condition does not require any correction at the 
present time  
ENT specialist consultation
Pathololgy of ENT organs are not detected
Chronic tonsilitis is compensated
CONSULTATION 
CLINICAL SYNDROMES
 Pericarditis
 Pericardial effusion
 Inflammation
 Splenomegaly
 Goiter
http://ddxof.com/pericardial-effusion/
Most cases are labeled as 
“Idiopathic” because the 
traditional diagnostic approach 
often fails to identify the 
etiology
Etiology of Pericarditis
Clinical Syndromes Classification
Pericarditis
2015 ESC Guidelines for the diagnosis and management of pericardial diseases 
Clinical Syndromes Classification
Pericardial effusion
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Clinical Syndromes Classification
Grading the size of an effusion by 
echocardiography measurements 
 Physiologic/trivial 
echo-free pericardial space < 5 mm ≈ 50-100 ml of fluid
 Small
echo-free pericardial space 6-9 mm ≈ 100-250 ml of fluid
 Moderate
echo-free pericardial space 10-19 mm ≈ 250-500 ml of 
fluid
 Large
echo-free pericardial space >20 mm ≈ >500 ml of fluid
Clinical Syndromes Classification
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Pericardial effusion
According to the composition of the fluid
 Serous
 Fibrinous
 Purulent
 Caseous
 Hemorrhagic
 Mixed
Clinical Syndromes Classification
INFLAMMATION
According to duration 
 Per-acute inflammation 
 Acute inflammation
 Sub-acute inflammation 
 Chronic inflammation 
According to etiology
• Biological inflammation
• Chemical
• Physical
• Immune factors
According to location
 Localized
 Widespread or Systemic
Clinical Syndromes Classification
SPLENOMEGALY
Primary causes 
 Immune response work 
hypertrophy 
 RBC destruction work 
hypertrophy 
 Congestive 
 Myeloproliferative
 Infiltrative
 Neoplastic
Miscellaneous causes 
• Trauma
• Cysts
• Hemangiomas
• Metastasis
• Giant abscess 
• Drug induced
Clinical Syndromes Classification
WHO goiter classification
Clinical Syndromes Classification
Goiter classification according to thyroid 
function
 Non-toxic goiter 
 Toxic goiter
 Hypothyroid goiter
Clinical Syndromes Classification
Goiter classification according to the thyroid 
structure
 Diffuse
 Nodular
Clinical Syndromes Classification
FINAL DIAGNOSIS
Main disease
Acute idiopathic serofibrinous (seroplastic) 
pericarditis with small amount of effusion
Complication 
Inflammatory splenomegaly
Concomitant disease
Diffuse non-toxic goiter grade I 
2015 ESC RECOMMENDATIONS FOR 
THE TREATMENT OF ACUTE PERICARDITIS
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
2015 ESC RECOMMENDATIONS FOR 
THE TREATMENT OF ACUTE PERICARDITIS
Drug Usual dosing Duration Tapering
Aspirin 750-1000 mg q8h 1-2 weeks for 
acute
weeks –months 
for chronic
Decrease dose by 250-
500 mg every 1-2 week
Ibuprofen 600mg q8h 1-2 weeks for 
acute
weeks –months 
for chronic
Decrease dose by 200-
400 mg every 1-2 week
Colchicine 0.5 mg qd (<70
kg)
0.5 mg bid (>70
kg)
3 months for 
acute
At least 6 
months for 
chronic
Not mandatory, 
alternatively 0.5 mg  
every other day(<70 kg) 
or 0.5 mg once(>70 kg) 
in the last weeks
Colchicine is added on the top of aspirin or ibuprofen.
Gastroprotection should be provided.
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
CORTICOSTEROIDS (Prednisone)
Starting dose 0.25-50 
mg/kg/day
Tapering
> 50 mg 10 mg/day every 1-2 weeks
50-25 mg 5-10 mg/day every 1-2 weeks
25-15 mg 2.5 mg/day every 2-4 weeks
<15 mg 1.25-2.5 mg/day every 2-6 
weeks
 Avoid higher doses except severe cases, and only for few days, with 
rapid tapering to 25 mg/day
 Every decrease in prednisone dose should be done only if the 
patient is asymptomatic and C-RP is normal
 Prevention of calcium loss: Ca supplements, vit D, biphosphonates
2015 ESC RECOMMENDATIONS FOR 
THE TREATMENT OF ACUTE PERICARDITIS
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Inflammation
 NSAIDs
Ibuprofen 600 mg qid
 Glucocorticoids
Methylprednisolone 24 mg at 7.00
8 mg at 13.00
14 days,  followed by dose tapering 4 mg every 2 weeks
 Gastroprotection
Pantoprazole 40 mg bid
MANAGEMENT OF THE PATIENT
Emperic antibiotic therapy
 IV ceftriaxone 1000 mg bid 
 IV levofloxacin 500 mg qd
Because of temperature and lab tests (neutrophilic
leucocytosis: WBC 13.7*10⁹/L, band 4%, segmented 
77%) were not normalized, antibiotic treatment 
continued by
 Azithromycin 500 qd 5 days
Protection against fungal infection
 Fluconazole 150mg qod # 5
7 days
MANAGEMENT OF THE PATIENT
 In this case prompt investigation, appropriate 
diagnosis, and efficient treatment led to recovery
 Symptoms abated
 Body temperature turned into normal: 36.6-36.9⁰C 
 Lab tests were normalized: WBC 7.8*10⁹/L
 Second echocardiogram after treatment revealed 
reduction of the effusion (posterior echo-free 
pericardial space 2 mm, anterior and apical echo-
free pericardial space were absent)
OUTCOME
OUTCOME
 Patient was discharged from the hospital
 It was recommended observation of the 
cardiologist and continuing methylprednisolone
tapering
 Clinical case displayed particular features of the 
acute pericarditis: course of disease, diagnostic 
consideration, treatment recommendations
 In this instance take place positive trend of illness 
against the background of the conservative
therapy
BUT
 15% to 30% of patients with acute pericarditis
recurrence may develop
 The risk of recurrence is higher for women and for
patients who do not have a response to initial
treatment with NSAIDs
CONCLUSION

